A randomized controlled trial: Effects of compression therapy combined with exercise on chemotherapy-induced peripheral neuropathy in patients with breast cancer

IF 2.4 Q3 Medicine Cancer treatment and research communications Pub Date : 2024-01-01 Epub Date: 2025-01-19 DOI:10.1016/j.ctarc.2025.100871

Yu Xiaoqian , Hu Jiwei , Zhou Lizhi , Guo Baojia , Guo Luyan , Xu Huiqian , Li Hong , Fan Yijing

{"title":"A randomized controlled trial: Effects of compression therapy combined with exercise on chemotherapy-induced peripheral neuropathy in patients with breast cancer","authors":"Yu Xiaoqian , Hu Jiwei , Zhou Lizhi , Guo Baojia , Guo Luyan , Xu Huiqian , Li Hong , Fan Yijing","doi":"10.1016/j.ctarc.2025.100871","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><div>To investigate the effects of compression therapy combined with exercise for cancer patients (EXCAP) in patients with peripheral neuropathy caused by breast cancer chemotherapy.</div></div><div><h3>Methods</h3><div>Overall, 108 patients with peripheral neuropathy after chemotherapy for breast cancer were randomly divided into the control group (routine nursing), experimental group 1 (compression therapy), and experimental group 2 (compression therapy and EXCAP). The National Institute of Cancer Drug Toxicity Rating Scale and the Chemotherapy-Induced Peripheral Neuropathy Assessment Tool were assessed and compared between groups.</div></div><div><h3>Results</h3><div>The incidence of grade 0 peripheral neuropathy in both experimental groups was higher than that in controls (<em>P</em> < 0.001), and the incidence in group 2 was higher than that in group 1 (<em>P</em> < 0.001). The incidence of grade 2 disease in both experimental groups was lower than that in controls (<em>P</em> < 0.001). The rate of symptoms in both experimental groups after the intervention were lower than that in the control group (<em>P</em> < 0.001), and those in experimental group 2 were lower than those in experimental group 1 (<em>P</em> < 0.001). Scores regarding activities of daily living in the experimental groups were lower than those of the control group (<em>P</em> < 0.001), and lower in group 2 than in group 1 (<em>P</em> < 0.001).</div></div><div><h3>Conclusion</h3><div>Compression therapy and EXCAP can effectively reduce the incidence of chemotherapy-induced peripheral neuropathy in patients undergoing breast cancer chemotherapy. They can both positively impact patients' daily lives and symptom experiences; however, they are more effective when combined.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"42 ","pages":"Article 100871"},"PeriodicalIF":2.4000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer treatment and research communications","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2468294225000097","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/19 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose

To investigate the effects of compression therapy combined with exercise for cancer patients (EXCAP) in patients with peripheral neuropathy caused by breast cancer chemotherapy.

Methods

Overall, 108 patients with peripheral neuropathy after chemotherapy for breast cancer were randomly divided into the control group (routine nursing), experimental group 1 (compression therapy), and experimental group 2 (compression therapy and EXCAP). The National Institute of Cancer Drug Toxicity Rating Scale and the Chemotherapy-Induced Peripheral Neuropathy Assessment Tool were assessed and compared between groups.

Results

The incidence of grade 0 peripheral neuropathy in both experimental groups was higher than that in controls (P < 0.001), and the incidence in group 2 was higher than that in group 1 (P < 0.001). The incidence of grade 2 disease in both experimental groups was lower than that in controls (P < 0.001). The rate of symptoms in both experimental groups after the intervention were lower than that in the control group (P < 0.001), and those in experimental group 2 were lower than those in experimental group 1 (P < 0.001). Scores regarding activities of daily living in the experimental groups were lower than those of the control group (P < 0.001), and lower in group 2 than in group 1 (P < 0.001).

Conclusion

Compression therapy and EXCAP can effectively reduce the incidence of chemotherapy-induced peripheral neuropathy in patients undergoing breast cancer chemotherapy. They can both positively impact patients' daily lives and symptom experiences; however, they are more effective when combined.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

一项随机对照试验：压迫疗法联合运动对化疗诱导的乳腺癌患者周围神经病变的影响。

目的：探讨肿瘤患者压迫联合运动治疗（EXCAP）对乳腺癌化疗后周围神经病变患者的治疗效果。方法：将108例乳腺癌化疗后周围神经病变患者随机分为对照组（常规护理）、实验1组（压迫治疗）、实验2组（压迫治疗+ EXCAP）。采用美国国家癌症研究所药物毒性评定量表和化疗引起的周围神经病变评估工具对两组患者进行评估和比较。结果：两组患者0级周围神经病变发生率均高于对照组（P < 0.001），且2组患者发生率高于1组（P < 0.001）。两组患者2级病变发生率均低于对照组（P < 0.001）。干预后两组患者的症状发生率均低于对照组（P < 0.001），且实验组2低于实验组1 （P < 0.001）。实验组患者日常生活活动能力得分低于对照组（P < 0.001）， 2组患者低于1组（P < 0.001）。结论：压迫治疗和EXCAP可有效降低乳腺癌化疗患者化疗性周围神经病变的发生率。它们既能对患者的日常生活和症状体验产生积极影响；然而，当它们结合使用时更有效。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Cancer treatment and research communications Medicine-Oncology

CiteScore

4.30

自引率

0.00%

发文量

148

审稿时长

56 days

期刊介绍： Cancer Treatment and Research Communications is an international peer-reviewed publication dedicated to providing comprehensive basic, translational, and clinical oncology research. The journal is devoted to articles on detection, diagnosis, prevention, policy, and treatment of cancer and provides a global forum for the nurturing and development of future generations of oncology scientists. Cancer Treatment and Research Communications publishes comprehensive reviews and original studies describing various aspects of basic through clinical research of all tumor types. The journal also accepts clinical studies in oncology, with an emphasis on prospective early phase clinical trials. Specific areas of interest include basic, translational, and clinical research and mechanistic approaches; cancer biology; molecular carcinogenesis; genetics and genomics; stem cell and developmental biology; immunology; molecular and cellular oncology; systems biology; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; cancer policy; and integration of various approaches. Our mission is to be the premier source of relevant information through promoting excellence in research and facilitating the timely translation of that science to health care and clinical practice.